Publications

2005

Roychowdhury M, Pambuccian SE, Aslan DL, Jessurun J, Rose AG, J Manivel C, et al. Pulmonary complications after bone marrow transplantation: an autopsy study from a large transplantation center. Arch Pathol Lab Med. 2005;129(3):366-71.
Jang B-, Paik J-, Kim S-, Shin D-, Song D-, Park J-, et al. Catalase induced expression of inflammatory mediators via activation of NF-kappaB, PI3K/AKT, p70S6K, and JNKs in BV2 microglia. Cell Signal. 2005;17(5):625-33.
Fadare O, Qin L, Martel M, Tavassoli FA. Pathology of the NovaSure (radio-frequency) impedance-controlled endometrial ablation system. Arch Pathol Lab Med. 2005;129(9):1175-8.
Ogino S, Kawasaki T, Brahmandam M, Yan L, Cantor M, Namgyal C, et al. Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn. 2005;7(3):413-21.
Leonard JP, Coleman M, Ketas J, Ashe M, Fiore JM, Furman RR, et al. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol. 2005;23(22):5044-51.
Chiarle R, Simmons WJ, Cai H, Dhall G, Zamò A, Raz R, et al. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med. 2005;11(6):623-9.
Allemand E, Guil S, Myers M, Moscat J, Caceres JF, Krainer AR. Regulation of heterogenous nuclear ribonucleoprotein A1 transport by phosphorylation in cells stressed by osmotic shock. Proc Natl Acad Sci U S A. 2005;102(10):3605-10.
Peng W, Zhang X, Mohamed N, Inghirami G, Takeshita K, Pecora A, et al. A DeImmunized chimeric anti-C3b/iC3b monoclonal antibody enhances rituximab-mediated killing in NHL and CLL cells via complement activation. Cancer Immunol Immunother. 2005;54(12):1172-9.
Kim HJ, Schleiffarth JR, Jessurun J, Sumanas S, Petryk A, Lin S, et al. Wnt5 signaling in vertebrate pancreas development. BMC Biol. 2005;3:23.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700